SNDX Syndax Pharmaceuticals Inc

Nasdaq Pharmaceutical Preparations DE CIK: 0001395937
AI RATING
HOLD
48% Confidence

Investment Thesis

Syndax demonstrates exceptional 627.8% YoY revenue growth indicating strong product-market fit and successful commercialization. However, the company remains deeply unprofitable with -52.7% operating margins and burns $50.3M annually, providing only ~2.6 years of runway at current burn rates. Fundamental viability depends critically on achieving profitability before cash reserves are exhausted.

Strengths

  • + Exceptional revenue growth of 627.8% YoY demonstrates validated product-market fit and successful commercialization
  • + Strong cash position of $130.9M with excellent liquidity ratios (5.47x current, 5.06x quick) provides substantial operating runway
  • + Conservative debt structure with Debt/Equity ratio of 0.48x and modest long-term debt of $20.0M

Risks

  • ! Severe operational cash burn of -$50.3M annually with only ~2.6 years of runway before cash depletion at current burn rates
  • ! Deeply unprofitable operations with -52.7% operating margin and -65.8% net margin despite massive revenue growth, indicating high unit costs or operating inefficiency
  • ! No visible path to profitability; company must demonstrate unit economics improvement and margin expansion to avoid cash crisis before achieving sustainable operations

Key Metrics to Watch

Financial Metrics

Revenue
64.9M
Net Income
-42.7M
EPS (Diluted)
$-0.48
Free Cash Flow
-50.5M
Total Assets
472.7M
Cash
130.9M

Profitability Ratios

Gross Margin N/A
Operating Margin -52.7%
Net Margin -65.8%
ROE -102.5%
ROA -9.0%
FCF Margin -77.9%

Balance Sheet & Liquidity

Current Ratio
5.47x
Quick Ratio
5.06x
Debt/Equity
0.48x
Debt/Assets
91.2%
Interest Coverage
-342.02x
Long-term Debt
20.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T18:55:16.604178 | Data as of: 2026-03-31 | Powered by Claude AI